Targeting the tumor microenvironment by immunotherapy: Part 2

Immunotherapy

Volumn 3, Issue 11, 2011, Pages 1385-1408

  Leibovici, Judith ^a   Itzhaki, Orit ^a   Huszar, Monica ^a   Sinai, Judith ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

cancer immunotherapy; growth promoting targets; immune evasion targets; immune targets; nonimmune targets; tumor microenvironment

Indexed keywords

BEVACIZUMAB; CHEMOKINE RECEPTOR; CLODRONIC ACID; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DASATINIB; DENILEUKIN DIFTITOX; GEMCITABINE; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HALOFUGINONE; IMMUNOTOXIN; INDOLEAMINE 2,3 DIOXYGENASE; INTEGRIN; INTERLEUKIN 10; MATRIX METALLOPROTEINASE; MICRORNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CT 011; MONOCLONAL ANTIBODY MSR1; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; PROGRAMMED DEATH 1 LIGAND 1; STAT3 PROTEIN; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

APOPTOSIS; BIOACCUMULATION; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CD25+ T LYMPHOCYTE; CELL THERAPY; CHEMOTHERAPY; DENDRITIC CELL; HORMONAL THERAPY; HUMAN; HYPOXIA; IMMUNE EVASION; IMMUNE RESPONSE; LYMPHOCYTE DEPLETION; MACROPHAGE; MOLECULAR MIMICRY; NEOPLASM; NONHUMAN; NUCLEAR REPROGRAMMING; PERICYTE; PRIORITY JOURNAL; RADIATION; REGULATORY T LYMPHOCYTE; REVIEW; SURGERY; TARGET CELL; TH2 CELL; TUMOR; TUMOR MICROENVIRONMENT;

ANIMALS; CLINICAL TRIALS AS TOPIC; ENDOTHELIAL CELLS; FIBROBLASTS; HUMANS; IMMUNE EVASION; IMMUNOTHERAPY; MICE; NEOPLASMS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 80755159088     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.112     Document Type: Review

References (241)

1. Somers SS. Surgical implications of tumour immunology. Ann. R. Coll. Surg. Engl. 78(2), 103-109 (1996). (Pubitemid 26083627)
2. Eilber FR, Morton DL. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer 25(2), 362-367 (1970).
3. Penn I. Posttransplant malignancies. Transplant. Proc. 31(1-2), 1260-1262 (1999). (Pubitemid 29127895)
4. Boshoff C, Weiss R. AIDS-related malignancies. Nat. Rev. Cancer 2(5), 373-382 (2002). (Pubitemid 37328950)
5. Pawelec G, Ouyang Q, Colonna Romano G, Candore G, Lio D, Caruso C. Is human immunosenescence clinically relevant? Looking for 'immunological risk phenotypes'. Trends Immunol. 23(7), 330-332 (2002). (Pubitemid 34717900)
6. Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene 27(45), 5894-5903 (2008).
7. Ehrlich H. Ueber den jetzigen Stand der Karcinomforschung. Ned. Tijdschr. Geneeskd 5(1), 273-290 (1909).
8. Thomas L. Discussion. In: Cellular and Humoral Aspects of the Hypersensitive States. Lawrence H (Ed.).Hoeber-Harper, NY, USA, 529-532 (1959).
9. Burnet FM. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1-27 (1970).
10. Foley EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 13(12), 835-837 (1953).
11. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J. Natl Cancer Inst. 18(6), 769-778 (1957).
12. Old LJ, Boyse EA. Specific antigens of tumors and leukemias of experimental animals. Med. Clin. North Am. 50(3), 901-912 (1966).
13. Rescigno M, Avogadri F, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. Biochim. Biophys. Acta 1776(1), 108-123 (2007). (Pubitemid 47332077)
14. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3(11), 991-998 (2002). (Pubitemid 35363648)
15. + T cells. World J. Surg. 19(3), 352-358 (1995).
16. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58(16), 3491-3494 (1998). (Pubitemid 28376536)
17. Galon J, Costes A, Sanchez Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006). (Pubitemid 44498003)
18. Clark WH Jr, Elder DE, Guerry DT et al. Model predicting survival in stage I melanoma based on tumor progression. J. Natl Cancer Inst. 81(24), 1893-1904 (1989). (Pubitemid 20026075)
19. Clemente CG, Mihm MC JR, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7), 1303-1310 (1996). (Pubitemid 26102328)
20. Rivoltini L, Carrabba M, Huber V et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol. Rev. 188, 97-113 (2002). (Pubitemid 35398868)
21. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004). (Pubitemid 39273730)
22. Klein G. Tumor antigens. Annu. Rev. Microbiol. 20, 223-252 (1966).
23. Hellstrom I, Hellstrom KE, Pierce GE, Yang JP. Cellular and humoral immunity to different types of human neoplasms. Nature 220(5174), 1352-1354 (1968).
24. Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol. Immunother. 55(10), 1185-1197 (2006). (Pubitemid 43992045)
25. + T cells in patients with melanoma. J. Immunol. 175(9), 6169-6176 (2005). (Pubitemid 41508105)
26. Anichini A, Vegetti C, Mortarini R. The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol. Immunother. 53(10), 855-864 (2004). (Pubitemid 39312653)
27. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J. Immunother 29(3), 233-240 (2006). (Pubitemid 44297291)
28. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4(1), 71-78 (2004). (Pubitemid 38082155)
29. Orimo A, Gupta PB, Sgroi DC et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF 1/CXCL12 secretion. Cell 121(3), 335-348 (2005). (Pubitemid 40692295)
30. Augsten M, Hagglof C, Olsson E et al. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc. Natl Acad. Sci. USA 106(9), 3414-3419 (2009).
31. Wu Y, Li YY, Matsushima K, Baba T, Mukaida N. CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. J. Immunol. 181(9), 6384-6393 (2008).
32. Dougan M, Dranoff G. Immune therapy for cancer. Annu. Rev. Immunol. 27, 83-117 (2009).
33. Stephan MT, Ponomarev V, Brentjens RJ et al. T cell-encoded CD80 and 4 1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 13(12), 1440-1449 (2007). (Pubitemid 350224246)
34. Finak G, Bertos N, Pepin F et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14(5), 518-527 (2008). (Pubitemid 351655218)
35. Farmer P, Bonnefoi H, Anderle P et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 15(1), 68-74 (2009).
36. Pietras K, Rubin K, Sjoblom T et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62(19), 5476-5484 (2002).
37. Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth - bystanders turning into key players. Curr. Opin Genet. Dev. 19(1), 67-73 (2009).
38. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 5(1), e19 (2008).
39. Scanlan MJ, Raj B, Calvo B et al. Molecular cloning of fibroblast activation protein a, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl Acad. Sci. USA 91(12), 5657-5661 (1994). (Pubitemid 24174387)
40. Cheng JD, Dunbrack RL Jr, Valianou M, Rogatko A, Alpaugh RK, Weiner LM. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 62(16), 4767-4772 (2002).
41. Santos AM, Jung J, Aziz N, Kissil JL, Pure E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 119(12), 3613-3625 (2009).
42. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 116(7), 1955-1962 (2006). (Pubitemid 44033319)
43. Ostermann E, Garin-Chesa P, Heider KH et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin. Cancer Res. 14(14), 4584-4592 (2008).
44. Gonda TA, Varro A, Wang TC, Tycko B. Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy? Semin. Cell Dev. Biol. 21(1), 2-10 (2010).
45. Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933), 1457-1461 (2009).
46. Scott AM, Wiseman G, Welt S et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9(5), 1639-1647 (2003). (Pubitemid 36554586)
47. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111(9), 1287-1295 (2003).
48. Erber R, Thurnher A, Katsen AD et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18(2), 338-340 (2004).
49. Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol. Blood Marrow Transplant 9(7), 417-425 (2003). (Pubitemid 38351799)
50. Granot I, Halevy O, Hurwitz S, Pines M. Halofuginone. an inhibitor of collagen type I synthesis. Biochim. Biophys. Acta 1156(2), 107-112 (1993). (Pubitemid 23049941)
51. Mcgaha T, Kodera T, Phelps R, Spiera H, Pines M, Bona C. Effect of halofuginone on the development of tight skin (TSK) syndrome. Autoimmunity 35(4), 277-282 (2002).
52. Gnainsky Y, Kushnirsky Z, Bilu G et al. Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF β signaling. Cell Tissue Res. 328(1), 153-166 (2007). (Pubitemid 46411910)
53. Sundrud MS, Koralov SB, Feuerer M et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 324(5932), 1334-1338 (2009).
54. Leiba M, Cahalon L, Shimoni A et al. Halofuginone inhibits NF k B and p38 MAPK in activated T cells. J. Leukoc. Biol. 80(2), 399-406 (2006). (Pubitemid 44835513)
55. Elkin M, Ariel I, Miao HQ et al. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res. 59(16), 4111-4118 (1999). (Pubitemid 29393586)
56. Gavish Z, Pinthus JH, Barak V et al. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 51(2), 73-83 (2002).
57. Nagler A, Ohana M, Shibolet O et al. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Eur. J. Cancer 40(9), 1397-1403 (2004). (Pubitemid 38737026)
58. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA. Cancer J. Clin. 60(4), 222-243 (2010).
59. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10(1), 9-22 (2010).
60. Avraamides C, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 8(8), 604-617 (2008).
61. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin a v b 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96(4), 1815-1822 (1995).
62. Mullamitha SA, Ton NC, Parker GJ et al. Phase I evaluation of a fully human anti-av integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin. Cancer Res. 13(7), 2128-2135 (2007). (Pubitemid 46649882)
63. Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur. J. Cancer 46(7), 1181-1188 (2010).
64. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141(1), 52-67 (2010).
65. Galvez BG, Matias-Roman S, Albar JP, Sanchez-Madrid F, Arroyo AG. Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J. Biol. Chem. 276(40), 37491-37500 (2001).
66. Chaudhary AK, Sing B, Bharti AC et al. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J. Biomed Sci .17, 10 (2010).
67. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J. Mammary Gland Biol. Neoplasia 15(2), 201-212 (2010).
68. Gialleli C, Theocharis AD, Karamanos NK. Roles of MMPs in cancer progression and their pharmacological targeting. FEBS J. 278(1), 16-27 (2011).
69. Betz M, Huxley P, Davies SJ et al. 1.8 A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase 8 complexed with a peptidomimetic hydroxamate primedside inhibitor with a distinct selectivity profile. Eur. J. Biochem. 247(1), 356-363 (1997). (Pubitemid 27319524)
70. Sapadin AM, Fleichmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J. Am. Acad. Dermatol. 54(2), 258-265 (2006).
71. Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of biphosphonates. Curr. Opin Pharmacol. 6(3), 307-312 (2006). (Pubitemid 43670914)
72. Falardeau P, Champagne P, Poyet P et al. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in Phase III clinical trials. Semin. Oncol. 28(6), 620-625 (2001). (Pubitemid 33134422)
73. Kousidou OC, Mitropoulou TN, Rousidis AE et al. Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors. Int. J. Oncol. 26(4), 1101-1109 (2005).
74. Gross J, Lapiere CM. Collagenolytic activity in amphibian tissue: a tissue culture assay. Proc. Natl Acad. Sci. USA 48, 1014-1022 (1962).
75. Lia NG, Shib ZH, Tang YP, Duan JA. Selective matrix metalloproteinase inhibitors for cancer. Curr. Med. Chem. 16(29), 3805-3827 (2009).
76. Dorman G, Cseh S, Haidu I et al. Matrix metalloproteinase inhibitor: a critical appraisal of design princilles and proposed therapeutic utility. Drugs 70(8), 949-964 (2010).
77. Rao VS, Dyer CE, Jameel JK, Drew PJ, Greenman J. Potential prognostic and therapeutic roles for cytokines in breast cancer (review).Oncol. Rep. 15(1), 179-185 (2006).
78. Kowalczyk DW, Wysocki PJ, Mackiewicz A. Cancer immunotherapy using cells modified with cytokine genes. Acta Biochim. Pol. 50(3), 613-624 (2003). (Pubitemid 38623796)
79. Kaufman HL, Deraffele G, Mitcham J et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J. Clin. Invest. 115(7), 1903-1912 (2005). (Pubitemid 40979730)
80. Dranoff G. GM CSF-based cancer vaccines. Immunol. Rev. 188, 147-154 (2002).
81. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90(8), 3539-3543 (1993). (Pubitemid 23111402)
82. Soiffer R, Lynch T, Mihm M et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 95(22), 13141-13146 (1998).
83. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two Phase III, randomized, vehicle-controlled studies. J. Am. Acad. Dermatol. 50(5), 722-733 (2004). (Pubitemid 38580549)
84. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J. Invest. Dermatol. 126(6), 1251-1255 (2006). (Pubitemid 43997904)
85. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13(8), 859-875 (2008).
86. Watowich SS, Liu YJ. Mechanisms regulating dendritic cell specification and development. Immunol. Rev. 238(1) 76-92 (2010).
87. Palucka K, Ueno H, Roberts L, Fay J, Banchereau J. Dendritic cells: are they critically relevant? Cancer J. 16(4) 318-324 (2010).
88. Palucka K, Ueno H, Fay J, Banchereau J. Dendritic cells and immunity against cancer. J. Intern. Med. 269(1) 64-73 (2010).
89. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin Immunol. 21(2), 233-240 (2009).
90. Besser MJ, Shapira-Frommer R, Treves AJ et al. Clinical responses in a Phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16(9), 2646-2655 (2010).
91. Hong JJ, Rosenberg SA, Dudley ME et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 16(19), 4892-4898 (2010).
92. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126-129 (2006). (Pubitemid 44547756)
93. Aharinejad S, Paulus P, Sioud M et al. Colony-stimulating factor 1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 64(15), 5378-5384 (2004). (Pubitemid 39006559)
94. Zeisberger SM, Odermatt B, Marty C, Zehnder Fjallman AH, Ballmer Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 95(3), 272-281 (2006). (Pubitemid 44187587)
95. Miselis NR, Wu ZJ, Van Rooijen N, Kane AB. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol. Cancer Ther. 7(4), 788-799 (2008). (Pubitemid 351551032)
96. Hiraoka K, Zenmyo M, Watari K et al. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci. 99(8), 1595-1602 (2008).
97. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9(4), 239-252 (2009).
98. Hagemann T, Lawrence T, McNeish I et al. "Re-educating" tumor-associated macrophages by targeting NF k B. J. Exp Med. 205(6),1261-1268 (2008).
99. Puig-Kroger A, Sierra-Filardi E, Dominguez-Soto A et al. Folate receptor b is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res. 69(24), 9395-9403 (2009).
100. Nagai T, Tanaka M, Tsuneyoshi Y et al. Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor b. Cancer Immunol. Immunother. 58(10), 1577-1586 (2009).
101. Herber DL Cao W, Nefedova Y et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 16(8), 880-886 (2010).
102. Pan PY, Wang GX, Yin B et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111(1), 219-228 (2008).
103. Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit. Rev. Oncol. Hematol. 77(1), 12-19 (2010).
104. Ozao-Choy J, Ma G, Kao J et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69(6), 2514-2522 (2009).
105. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells. Adv. Exp. Med. Biol. 601, 213-223 (2007).
106. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int. Immunopharmacol. 9(7-8), 900-909 (2009).
107. De Palma M, Venneri Ma, Galli R et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8(3), 211-226 (2005). (Pubitemid 41317592)
108. Ercolini AM, Ladle BH, Manning EA et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 201(10), 1591-1602 (2005). (Pubitemid 40723662)
109. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL 2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T cell immunity. Blood 110(9), 3192-3201 (2007). (Pubitemid 350106311)
110. Fridlender ZG, Buchlis G, Kapoor V et al. CCL2 blockade augments cancer immunotherapy. Cancer Res. 70(1), 109-118 (2010).
111. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin 2 receptor a) monoclonal antibody. Cancer Res. 59(13), 3128-3133 (1999). (Pubitemid 29316012)
112. + regulatory T cells. J. Exp. Med. 202(7), 885-891 (2005). (Pubitemid 41396888)
113. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA 4 blockade. Science 271(5256), 1734-1736 (1996). (Pubitemid 26102823)
114. Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100(8), 4712-4717 (2003). (Pubitemid 36457795)
115. Nizar S, Meyer B, Galustian C, Kumar D, Dalgleish A. T regulatory cells, the evolution of targeted immunotherapy. Biochim. Biophys. Acta 1806(1), 7-17 (2010).
116. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100(14), 8372-8377 (2003). (Pubitemid 36842552)
117. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6(4), 295-307 (2006).
118. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T cells. Cancer Res. 48(6), 1671-1675 (1988). (Pubitemid 18091225)
119. Ryan AE, Shanahan F, O'Connell J, Houston AM. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res. 65(21), 9817-9823 (2005). (Pubitemid 41541459)
120. + T cells. Immunol. Lett. 122(1), 30-36 (2009).
121. Hirano F, Kaneko K, Tamura H et al. Blockade of B7 H1 and PD 1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65(3), 1089-1096 (2005). (Pubitemid 40216472)
122. Berger R, Rotem-Yehudar R, Slama G et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD 1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14(10), 3044-3051 (2008).
123. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7 H1 promotes T cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793-800 (2002).
124. Smits EL, Ponsaerts P, Bernerman ZM, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13(8), 859-875 (2008).
125. Smith KJ, Hamza S, Skelton H. The imidazoquinolines and their place in the therapy of cutaneous disease. Exp. Opin Pharmacother. 4(7), 1105-1119 (2003). (Pubitemid 36857192)
126. Shukla NM, Malladi SS, Mutz CA et al. Structure-activity relationship in human toll-like receptor 7-active imideazoquinoline analogues. J. Med. Chem. 53(11), 4450-4465 (2010).
127. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA 4 therapy: immune monitoring during clinical development of a novel immunotherapy. Semin. Oncol. 37(5), 473-484 (2010).
128. Page DB, Yuan J, Wolchok JD. Targeting cytotoxic T lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. Immunotherapy 2(3), 367-379 (2010).
129. O'Day S, Weber J, Lebbe C et al. Effect of ipilimumab treatment on 18 month survival: update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three Phase II clinical trials. Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May-2 June 2009.
130. Slettenaar VI, Wilson JL. The chemokine network: a target in cancer biology? Adv. Drug Deliv. Rev. 58(8), 962-974 (2006). (Pubitemid 44780906)
131. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol. 14(3), 171-179 (2004). (Pubitemid 38586742)
132. Moskovits N, Kalinkovich A, Bar J, Lapidot T, Oren M. p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res. 66(22), 10671-10676 (2006). (Pubitemid 44876961)
133. Loberg RD, Ying C, Craig M et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 67(19), 9417-9424 (2007). (Pubitemid 47535932)
134. Stathopoulos GT, Psallidas I, Moustaki A et al. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J. Natl Cancer Inst. 100(20), 1464-1476 (2008).
135. Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med. 16(3), 133-144 (2010).
136. Zigler M, Villares GJ, Lev DC, Melnikova VO, Bar-Eli M. Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am. J. Clin. Dermatol. 9(5), 307-311 (2008).
137. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor b signaling in T cells. Nat. Med. 7(10), 1118-1122 (2001). (Pubitemid 33010019)
138. Seo N, Hayakawa S, Takigawa M, Tokura Y. Interleukin 10 expressed at early tumour sites induces subsequent generation of CD4(+) T regulatory cells and systemic collapse of antitumour immunity. Immunology 103(4), 449-457 (2001). (Pubitemid 32744391)
139. Mosser DM, Zhang X. Interleukin 10: new perspectives on an old cytokine. Immunol. Rev. 226, 205-218 (2008).
140. Nam JS, Terabe M, Mamura M et al. An anti-transforming growth factor b antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 68(10), 3835-3843 (2008).
141. Liu Y, Wang Q, Kleinschmidt Demasters BK, Franzusoff A, Ng KY, Lillehei KO. TGF β inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors. J. Neurooncol. 81(2), 149-162 (2007). (Pubitemid 44963973)
142. Tritschler I, Gramatzki D, Capper D et al. Modulation of TGF β activity by latent TGF β-binding protein 1 in human malignant glioma cells. Int. J. Cancer 125(3), 530-540 (2009).
143. Moutsopoulos NM, Wen J, Wahl SM. TGF β and tumors - an ill-fated alliance. Curr. Opin Immunol. 20(2), 234-240 (2008).
144. Ahirwar DK, Agrahari A, Mandhani A, Mittal RD. Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. Biomarkers 14(4), 213-218 (2009).
145. Basturk B, Yavascaoglu I, Oral B, Goral G, Oktay B. Cytokine gene polymorphisms can alter the effect of Bacillus Calmette-Guerin (BCG) immunotherapy. Cytokine 35(1-2), 1-5 (2006). (Pubitemid 44485528)
146. Massague J. TGF β in cancer. Cell 134(2), 215-230 (2008).
147. Uhl M, Aulwurm S, Wischhusen J et al. SD 208, a novel transforming growth factor b receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64(21), 7954-7961 (2004). (Pubitemid 39446929)
148. Friese MA, Wischhusen J, Wick W et al. RNA interference targeting transforming growth factor b enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 64(20), 7596-7603 (2004). (Pubitemid 39372105)
149. + T cells infiltrating prostatic tumors are induced to become suppressor cells. J. Immunol 183(8), 4848-4852 (2009).
150. Kobie JJ, Wu RS, Kurt RA et al. Transforming growth factor b inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 63(8), 1860-1864 (2003). (Pubitemid 36460849)
151. + regulatory T cells. Int. Immunopharmacol. 8(4),542-547 (2008).
152. Qian Bf, Wahl SM. TGF β can leave you breathless. Curr. Opin Pharmacol. 9(4), 454-461 (2009).
153. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Exp. Opin Investig. Drugs 18(1), 45-56 (2009).
154. Turkson J. STAT proteins as novel targets for cancer drug discovery. Exp. Opin Ther. Targets 8, 409-422 (2004). (Pubitemid 39359648)
155. Yu H, Jove R. The STATs of cancer: new molecular targets come of age. Nat. Rev. Cancer 4, 97-105 (2004). (Pubitemid 38198738)
156. Darnell JE. Validating STAT3 in cancer therapy. Nat. Med. 11, 595-596 (2005).
157. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7(1), 41-51 (2007). (Pubitemid 46020826)
158. Gamero AM, Young HA, Wiltrout RH. Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer? Cancer Cell 5(2), 111-112 (2004). (Pubitemid 38283795)
159. Catlett-Falcone R, Landowski TH, Oshiro MM et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10(1), 105-115 (1999). (Pubitemid 29077388)
160. Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev. 24(2), 315-327 (2005). (Pubitemid 40922802)
161. Xu Q, Briggs J, Park S et al. Targeting Stat3 blocks both HIF 1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24(36), 5552-5560 (2005). (Pubitemid 43119350)
162. Fujita M, Zhu X, Sasaki K et al. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J. Immunol. 180(4), 2089-2098 (2008).
163. Turkson J, Kim JS, Zhang S et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther. 3(3), 261-269 (2004). (Pubitemid 39193701)
164. Siddiquee KA, Gunning PT, Glenn M et al. An oxazole-based small molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem. Biol. 2, 787-798 (2007). (Pubitemid 351166054)
165. Nagel-Wolfrum K, Buerger C, Wittig I, Butz K, Hoppe-Sevler F, Groner B. The interaction of specific peptide aptamers with the DNA binding domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol. Cancer Res. 2(3), 170-182 (2004). (Pubitemid 39030307)
166. Song H, Wang R, Wang S, Lin J. A low molecular weight compound discovered through virtual data base screening inhibits Stat3 function in breast cancer cells. Proc. Natl Acad. Sci. USA 102(13), 4700-4705 (2005). (Pubitemid 40471517)
167. Turkson J, Zhang S Mora LB, Burns A, Sebti S, Jove R. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J. Biol. Chem. 280(38), 32979-32988 (2005). (Pubitemid 41368347)
168. Turkson J, Zhang S, Palmer J et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol. Cancer Ther. 3(12), 1533-1542 (2004). (Pubitemid 40136708)
169. Gao L, Zhang L, Hu J et al. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNA suppresses growth of human prostate tumor in vivo. Clin. Cancer Res. 11(17), 6333-6341 (2005). (Pubitemid 41262965)
170. Zhang X, Zhang J, Wang L et al. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 7, 149-159 (2007).
171. Blaskovich MA, Sun J, Cantor A Turkson J, Jove R, Sebti SM. Discovery of JSI 124 (cucurbitacin 1), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63(6), 1270-1279 (2003). (Pubitemid 36348705)
172. Kotha A, Sekharam M, Cilenti L et al. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther. 5(3), 621-629 (2006).
173. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL 6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol. 171(7), 3863-3871 (2003). (Pubitemid 37254592)
174. Guo Y, Nemeth J, O'Brien C et al. Effects of siltuximab on the IL 6-induced signaling pathway in ovarian cancer. Clin. Cancer Res. 16(23), 5759-5769 (2010).
175. Chen J, Bai L, Bernard D et al. Structure-based design and conformationally constraned cell-permeable STAT3 inhibitors. ACS Med. Chem. Lett. 1(2) 85-89 (2010).
176. Zhang X, Yue P, Fletcher S, Zhao N, Gunning PT, Turkson J. A novel small molecule disrupts STAT3 SH2 domain-phosphotyrosine interaction and STAT-dependent tumor processes. Biochem. Pharmacol. 79(10), 1398-1409 (2010).
177. Liu Y, Li PK, Lin J. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL 6 in human liver cancer cells. J. Biol. Chem. 285(35), 27249-27439 (2010).
178. Korpal M, Kang Y. Targeting the transforming growth factor b signalling pathway in metastatic cancer. Eur. J. Cancer 46(7), 1232-1240 (2010).
179. Kortylewski M, Yu H. Stat3 as a potential target for cancer immunotherapy. J. Immunother. 30(2), 131-139 (2007). (Pubitemid 46667794)
180. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281(5380), 1191-1193 (1998). (Pubitemid 28406294)
181. Lob S, Konigsrainer A. Role of IDO in organ transplantation: promises and difficulties. Int. Rev. Immunol. 28(3-4), 185-206 (2009).
182. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P. Inhibitors of indoleamine 2,3 dioxygenase for cancer therapy: can we see the wood for the trees? Nat. Rev. Cancer 9(6), 445-452 (2009).
183. Sorensen RB, Berge-Hansen L, Junker N et al. The immune system strikes back: cellular immune responses against indoleamine 2,3 dioxygenase. PLoS ONE 4(9), E6910 (2009).
184. Kobayashi S, Zimmermann H, Millhorn DE. Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport. J. Neurochem. 74(2), 621-632 (2000). (Pubitemid 30053734)
185. Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 57(13), 2602-2605 (1997). (Pubitemid 27283766)
186. Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin. Cancer Res. 14(19), 5947-5952 (2008).
187. Lukashev D, Sitkovsky M, Ohta A. From "Hellstrom paradox" to anti-adenosinergic cancer immunotherapy. Purinergic Signal 3(1-2), 129-134 (2007).
188. Sasaki K, Kohanbash G, Hoji A et al. miRNA 17 92 expression in differentiated T cells - implications for cancer immunotherapy. J. Transl. Med. 8, 17 (2010).
189. Nowak AK Lake RA, Robinson BW. Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv. Drug Deliv. Rev. 58(8), 975-990 (2006). (Pubitemid 44780907)
190. Lake RA, Robinson BW. Immunotherapy and chemotherapy-α practical partnership. Nat. Rev. Cancer 5(5), 397-405 (2005).
191. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105(7), 2862-2868 (2005). (Pubitemid 40446280)
192. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56(5), 641-648 (2007). (Pubitemid 46348738)
193. Reits EA, Hodge JW, Herberts CA et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203(5), 1259-1271 (2006). (Pubitemid 43736595)
194. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ. Combination of T cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62(5), 1462-1470 (2002). (Pubitemid 34407808)
195. Gough MJ Crittenden MR. Combination approaches to immunotherapy: the radiotherapy example. Immunotherapy 1(6), 1025-1037 (2009).
196. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 10(7), 718-726 (2009).
197. Gulley JL, Arlen PM, Bastian A et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res. 11(9), 3353-3362 (2005).
198. Chi Kh, Liu SJ, Li CP et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J. Immunother. 28(2), 129-135 (2005).
199. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE 4(11), E7965 (2009).
200. Kim KJ, Wang L, Su YC et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin. Cancer Res. 12(4), 1292-1298 (2006). (Pubitemid 43342521)
201. Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T. Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene. Ther. 11(6), 419-430 (2004). (Pubitemid 38747373)
202. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM, Postovit LM. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat. Rev. Cancer 7(4), 246-255 (2007). (Pubitemid 46480969)
203. Pierce GB, Pantazis CG, Caldwell JE, Wells RS. Specificity of the control of tumor formation by the blastocyst. Cancer Res. 42(3), 1082-1087 (1982). (Pubitemid 12141223)
204. Gerschenson M, Graves K, Carson SD, Wells RS, Pierce GB. Regulation of melanoma by the embryonic skin. Proc. Natl Acad. Sci. USA 83(19), 7307-7310 (1986). (Pubitemid 16000510)
205. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ. A three-dimensional model to study the epigenetic effects induced by the microenvironment of human embryonic stem cells. Stem Cells 24(3), 501-505 (2006). (Pubitemid 44464753)
206. Kulesa PM, Kasemeier-Kulesa JC, Teddy JM et al. Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. Proc. Natl Acad. Sci. USA 103(10), 3752-3757 (2006). (Pubitemid 43376627)
207. Topczewska JM, Postovit LM, Margaryan NV et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat. Med. 12(8), 925-932 (2006). (Pubitemid 44175144)
208. Adkins HB, Bianco C, Schiffer SG et al. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J. Clin. Invest. 112(4), 575-587 (2003). (Pubitemid 38056342)
209. Xing PX, Hu XF, Pietersz GA, Hosick HL, Mckenzie IF. Cripto: a novel target for antibody-based cancer immunotherapy. Cancer Res. 64(11), 4018-4023 (2004). (Pubitemid 38697318)
210. Casal C, Torres-Collado AX, Plaza-Calonge Mdel C et al. ADAMTS1 contributes to the acquisition of an endothelial-like phenotype in plastic tumor cells. Cancer Res. 70(11), 4676-4686 (2010).
211. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27(45), 5904-5912 (2008).
212. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T cell-based active immunotherapy. Trends Immunol. 24(6), 335-342 (2003).
213. Wahl SM, Wen J, Moutsopoulos N. TGF β: a mobile purveyor of immune privilege. Immunol. Rev. 213, 213-227 (2006). (Pubitemid 44401503)
214. Streilein JW. Tissue barriers, immunosuppressive microenvironments, and privileged sites: the eye's point of view. Reg. Immunol. 5(5), 253-268 (1993). (Pubitemid 24095090)
215. Pollack IF, Lund RD. The blood-brain barrier protects foreign antigens in the brain from immune attack. Exp. Neurol. 108(2), 114-121 (1990). (Pubitemid 20153931)
216. Head JR, Billingham RE. Immune privilege in the testis. II. Evaluation of potential local factors. Transplantation 40(3), 269-275 (1985). (Pubitemid 15023186)
217. Hofmeister V, Schrama D, Becker JD. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol. Immunother. 57(1), 1-17 (2008). (Pubitemid 350043655)
218. Josson S, Matsuoka Y, Chung LW, Zhau HE, Wang R. Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin. Cell Dev. Biol. 21(1), 26-32 (2010).
219. Erez N, Coussens LM. Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. Int. J. Cancer 128(11) 2536-2544 (2011).
220. Leibovici J, Itzhaki O, Kaptzan T. et al. Designing ageing conditions in tumor microenvironment - a new possible modality for cancer treatment. Mech. Ageing Dev. 130 (1-2), 76-85 (2009).
221. Lustgarten J. Cancer immunotherapy: focusing on the young, neglecting the old. Future Oncol. 6(6), 873-876 (2010).
222. Ershler WB, Stewart JA, Hacker MP, Moore AL, Tindle BH. B16 murine melanoma and aging: slower growth and longer survival in old mice. J. Natl Cancer Inst. 72(1), 161-164 (1984). (Pubitemid 14159243)
223. Donin N, Sinai J, Staroselsky A, Mahlin T, Nordenberg J, Leibovici J. Comparison of growth rate of two B16 melanomas differing in metastatic potential in young versus middle-aged mice. Cancer Invest. 15(5), 416-421 (1997). (Pubitemid 27439227)
224. Ershler WB. Why tumors grow more slowly in old people. J. Natl Cancer Inst. 77(4),837-839 (1986). (Pubitemid 16031844)
225. Fisher CJ, Egan MK, Smith P, Wicks K, Millis RR, Fentiman IS. Histopathology of breast cancer in relation to age. Br. J. Cancer 75(4), 593-596 (1997). (Pubitemid 27085305)
226. Cameron IL. Cell proliferation and renewal in aging mice. J. Gerontol. 27(2), 162-172 (1972).
227. Itzhaki O, Kaptzan T, Skutelsky E et al. Age-adjusted antitumoral therapy based on the demonstration of increased apoptosis as a mechanism underlying the reduced malignancy of tumors in the aged. Biochim. Biophys. Acta 1688(2), 145-159 (2004). (Pubitemid 38264409)
228. Pili R, Guo Y, Chang J, Nakanishi H, Martin GR, Passaniti A. Altered angiogenesis underlying age-dependent changes in tumor growth. J. Natl Cancer Inst. 86(17), 1303-1314 (1994). (Pubitemid 24276792)
229. Kaptzan T, Skutelsky E, Itzhaki O et al. Efficacy of anti-angiogenic treatment of tumors in old versus young mice. Mech. Ageing Dev. 127(4), 398-409 (2006). (Pubitemid 43290544)
230. Kaesberg PR, Ershler WB. The importance of immunesenescence in the incidence and malignant properties of cancer in hosts of advanced age. J. Gerontol. 44(6), 63-66 (1989). (Pubitemid 19282270)
231. Kaptzan T, Skutelsky E, Itzhaki O et al. Age-dependent differences in the efficacy of cancer immunotherapy in C57BL and AKR mouse strains. Exp. Gerontol. 39(7), 1035-1048 (2004). (Pubitemid 38952884)
232. Donin N, Sinai J, Michowitz M, Hiss J, Nordenberg J, Leibovici J. Role of immune response as determinant of tumor progression in function of host age in the B16 melanoma. Mech. Ageing Dev. 80(2), 121-137 (1995).
233. Yen SS, Laughlin GA. Aging and the adrenal cortex. Exp. Gerontol. 33(7-8), 897-910 (1998). (Pubitemid 29019344)
234. Nakamura K, Fushimi K, Kouchi H et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α and angiotensin II. Circulation 98(8), 794-799 (1998). (Pubitemid 28391845)
235. Reed MJ, Edelberg JM. Impaired angiogenesis in the aged. Sci. Aging Knowledge Environ. 2004(7), pe7 (2004).
236. Franceschi C, Bonafe M, Valensin S. Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine 18(16), 1717-1720 (2000). (Pubitemid 30109535)
237. Whiteside TL. Immune responses to malignancies. J. Allergy Clin. Immunol. 125(2 Suppl. 2), S272-S283 (2010).
238. Leibovici J. A model for the study of the long duration pathogenesis of cancer and its relevance to therapy. Med. Hypotheses 10(1), 105-112 (1983). (Pubitemid 13155223)
239. Leibovici J. Serial passage of tumors in mice in the study of tumor progression and testing of antineoplastic drugs. Cancer Res. 44(5), 1981-1984 (1984). (Pubitemid 14145142)
240. Rodriguez PC, Ochoa AC. Arginine regulation by myeloid-derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222, 180-191 (2008). (Pubitemid 351430370)
241. Fridlender ZG, Sun J, Kim S et al. Polarization of tumor-associated neutrophil phenotype by TGF-b: "N1" versus N2 TAN. Cancer Cell 16(3), 183-194 (2009).